IM Cannabis Corp

IM Cannabis Corp. engages in the production and sale of medical cannabis products. It offers dry flower products and cannabis oil products under the IMC brand. The company was founded on March 7, 1980 and is headquartered in Glil Yam, Israel.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IM Cannabis Corp. (NASDAQ:IMCC ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Anna Taranko - Director of Investor and Public Relations Oren Shuster - Chief Executive Officer Uri Birenberg - Chief Financial Officer Conference Call Participants Operator Good morning, and welcome to IM Cannabis' Third Quarter 2024 Earnings Conference Call. Today's conference call is being recorded.

IM Cannabis Corp. (IMCC) Q3 2024 Earnings Call Transcript

IMC pairs a +12% increase in revenue with a -16% decrease in the total operating expenses, building a solid foundation to deliver in 2025. TORONTO and GLIL YAM, Israel , Nov. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the third quarter ended September 30, 2024.

IM Cannabis Reports Third Quarter Financial Results

TORONTO and GLIL YAM, Israel , Nov. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the third 2024 ended September 30, 2024, on November 14, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community.

IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November 14th at 9:00am ET

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel , Oct. 4, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it intends to undertake a non-brokered private placement offering of up to US$1,613,000 through the sale of approximately 625,000 units (each, an "Unit") at a price per Unit (the "Offering Price") calculated on the basis of the deemed price per common shares in the capital of the Company (each, a "Share") equal to the 10-day volume weighted average price of the Shares on Canadian Securities Exchange (the "Exchange") ending on the trading day preceding October 3, 2024. Each Unit will be comprised of one Share and one Share purchase warrant (each, a "Warrant").

IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by Management

TORONTO and GLIL YAM, Israel , Oct. 2, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH ("IMC Germany"), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products.

IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2

TORONTO and GLIL YAM, Israel , Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr.

IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

IM Cannabis Corp. (NASDAQ:IMCC ) Q2 2024 Earnings Conference Call August 14, 2024 9:00 AM ET Company Participants Anna Taranko - Director of Investor and Public Relations Oren Shuster - Chief Executive Officer Uri Birenberg - Chief Financial Officer Conference Call Participants Scott Fortune - ROTH MKM Aaron Grey - Alliance Global Partners Operator Good morning, and welcome to IM Cannabis' Second Quarter 2024 Earnings Conference Call. Today's conference call is being recorded.

IM Cannabis Corp. (IMCC) Q2 2024 Earnings Call Transcript

IM Cannabis Corp. (IMCC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.14 per share a year ago.

IM Cannabis Corp. (IMCC) Reports Q2 Loss, Tops Revenue Estimates

IMC Germany delivers +200% in sales in first three months after German legalization, while overall revenue grows 12% vs Q2 2023 TORONTO and GLIL YAM, Israel, Aug. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2023, unless otherwise stated.

IM Cannabis Reports Second Quarter Financial Results

TORONTO and GLIL YAM, Israel , Aug. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2024 ended June 30, 2024, on Wednesday, August 14, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community.

IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET

TORONTO and GLIL YAM, Israel , July 29, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced that on July 26, 2024, it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requirement"). IMC is now in compliance with all applicable listing standards and will continue to be listed and traded on the NASDAQ Stock Market.

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Corp. IMCC, a leading medical marijuana company announced that its common shares are trading on a 6:1 post-consolidated basis.

IM Cannabis Shares Surge 586% After 6:1 Consolidation: What Investors Need To Know

TORONTO and GLIL YAM, Israel , July 12, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IM Cannabis"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further to its press release dated July 5, 2024, effective today the Company's common shares ("Common Shares") are trading on the Canadian Securities Exchange (the "CSE") and Nasdaq Stock Market LLC ("NASDAQ") on a 6:1 post-consolidated basis (the "Consolidation"). The Company's trading symbol remains "IMCC" on both the CSE and NASDAQ.

IM Cannabis Shares Commence Trading on 6:1 Consolidated Basis

Toronto, Ontario--(Newsfile Corp. - Le 9 juillet/July 2024) - IM Cannabis Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 2,232,357 common shares.

CSE Bulletin: Consolidation - IM Cannabis Corp. (IMCC)

TORONTO and GLIL YAM, Israel, July 5, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, announces that the board of directors of the Company (the "Board") has approved a consolidation of its issued and outstanding common shares ("Common Shares") on the basis of one post-consolidated Common Share for every six pre-consolidated Common Shares (the "Consolidation"). The Board has set July 12, 2024 as the effective date of the Consolidation and anticipates the Common Shares to trade on a post-consolidated basis effective July 12, 2024, subject to final confirmation from the Canadian Securities Exchange (the "CSE") and Nasdaq Stock Market LLC (the "NASDAQ").

IM Cannabis Announces Intention to Complete Consolidation

IMC Germany's accelerated growth potential leans strongly on its supply strategy through its ability to partner with cannabis growers for EU-GMP certification, bolstering the company's supply chain with exclusive product TORONTO and GLIL YAM, Israel , June 5, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is experiencing accelerated growth in Germany after the April 1 st partial legalization, further to the Company's press release dated March 25, 2024. Adjupharm GmbH's, IMC's German subsidiary ("Adjupharm" or "IMC Germany"), is supporting its growth by further bolstering its supply chain with an additional EU-GMP supplier, GlassHouse Botanics Inc. ("GlassHouse Botanics"), headquartered in Whitewater, Ontario.

IMCC Addresses Accelerated Growth in Germany Through new Supply Agreement with EU-GMP Certified Glasshouse Botanics and Announces a Change to its Board of Directors

Through continuous, active cost management, IMC reduced its annual G&A costs by 49% in 2023 and is now looking to significantly reduce its financial costs. TORONTO and GLIL YAM, Israel , May 29, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that in order to preserve its cash for to support accelerated growth in Germany it has closed a non-brokered private placement (the "Offering") of secured convertible debentures of the Company (each, a "Debenture") for aggregate proceeds of $2,091,977.

IM Cannabis Closes Convertible Debenture Offering to Support Accelerated Growth in Germany

IM Cannabis Corp. [IMCC] Q1 2024 Earnings Conference Call May 8, 2024 9:00 AM ET Company Participants Oren Shuster - CEP Uri Birenberg - CFO Anna Taranko - IR Conference Call Participants Scott fortune - ROTH MKM Aaron Gray - Alliance Global Partners Operator Good morning, and welcome to IM Cannabis' first quarter 2024 earnings conference call. Today's conference call is being recorded.

IM Cannabis Corp. (IMCC) Q1 2024 Earnings Call Transcript

IM Cannabis Corp. (IMCC) came out with a quarterly loss of $0.16 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.

IM Cannabis Corp. (IMCC) Reports Q1 Loss, Tops Revenue Estimates

IMC prepares for accelerated growth after legalization in Germany and recovers from the impact of the Israel-Hamas war. TORONTO and GLIL YAM, Israel , May 8, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2024.

IM Cannabis Reports First Quarter Financial Results

IM Cannabis (NASDAQ: IMCC ) stock is rocketing higher on Wednesday following news that President Joe Biden's Administration plans to reclassify marijuana. According to insider sources, the Biden Administration is planning to reclassify marijuana from a Schedule I drug to a Schedule III drug.

Why Is IM Cannabis (IMCC) Stock Up 49% Today?

TORONTO and GLIL YAM, Israel , May 1, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2024 ended March 31, 2024, on Wednesday, May 8, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community.

IM Cannabis to Report First Quarter 2024 Financial Results on Wednesday, May 8th at 9:00am ET

Canopy Growth

Innovative Industrial Properties

The progress toward legalization of cannabis in the United States continues at a slow pace, but medical marijuana is now permitted in approximately 37 states. Germany recently became the latest country to legalize cannabis for personal use beginning in April, coinciding with the informal holiday of 4/20.

Puff, Puff, Invest: 3 Top Cannabis Stock Picks to Celebrate 4/20

TORONTO and GLIL YAM, Israel , April 16, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company" or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd.

IMC to transfer its Oranim Pharmacy shares back to the seller

In the ever-evolving landscape of the US cannabis industry, marijuana stocks have been lighting up the market, with some experiencing triple-digit gains in the last month. Investors are keenly watching these volatile but potentially lucrative investments. The surge in interest comes as the industry sees an upward trajectory, buoyed by increasing legalization efforts and a growing acceptance of cannabis for both medical and recreational use. With the sector's projected expansion, savvy investors are diving into the market. However, it's crucial to approach these opportunities with a solid strategy, employing technical analysis and proper risk management to navigate the inherent risks.

News for IM Cannabis Corp Stock (IMCC)